Read about Blackmores' strategy overhaul in the wake of weak Q3 results, Bod Australia's continuing CBD innovations, Sirio Pharma's global R&D plans, and probiotics news from BLIS Technologies and Indian start-up MO's Superfoods.
CBD firm Bod Australia has embarked on a first-of-its-kind clinical trial on medical cannabis for Tourette syndrome patients, while continuing to expand its supplements business in countries with a more conducive regulatory environment than its home market.
Read about who won big at Natural Health Products New Zealand industry awards, China's crackdown on health foods and probiotics regulations, and the latest research and innovations in the Oceanic region.
Read about latest the regulatory developments in China, Blackmores' acerbic response to the MBA's "attack" on complementary medicine, and the mystery of India's missing fortified flour in our regulatory review.
The Medical Board of Australia's (MBA) proposal to reassess the regulation of complementary medicines and practitioners who prescribe them has elicited a strongly worded response from Marcus Blackmore.